Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Interferon (IFN)-α has reigned supreme for decades as biotech's blockbuster antiviral. That looks set to change with a raft of antibody and nucleic acid therapies progressing through the pipeline.
Almost 15 years after Ian Frazer began the work that created the first vaccine to prevent cervical cancer caused by human papilloma virus (HPV), the 54-year-old immunologist is using his newfound prominence to educate others about treating HPV and to pass along the lessons he's learned about drug development.